Ventax 100mg
Venetaclax
Ventax 100mg (Venetoclax) is used to treat CLL, SLL, and AML in adults, especially those unsuitable for intensive chemotherapy.
- Strengths 100 mg
- Form Tablets
- Packaging Size 3 x 10
- Packaging Type Box
- Manufacturer Pfizer Ltd
Description of Ventax 100mg
Ventax 100mg contains Venetoclax, a targeted cancer therapy used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). For AML, it is prescribed in combination with azacitidine, decitabine, or low-dose cytarabine, especially in elderly patients or those unfit for intensive chemotherapy. Ventax 100mg works by blocking the BCL-2 protein, which helps cancer cells survive, thereby triggering their natural death. The medicine is taken orally under medical supervision and requires regular monitoring due to risks such as tumor lysis syndrome. Always follow your doctor’s dosage and dietary instructions carefully.
Ingredients of Ventax 100mg
- Lorlatinib
Usage of Ventax 100mg
- The recommended dosage is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
- Swallow tablets whole; do not chew, crush, or split.
- Take at the same time each day. If a dose is missed and the next dose is due within 4 hours, skip the missed dose. Do not take two doses simultaneously to make up for a missed dose.
- If vomiting occurs after taking Lornatib, continue with the next scheduled dose without taking an additional dose.
Precautions for Ventax 100mg
- Drug Interactions: Avoid concomitant use with strong CYP3A inducers (e.g., rifampin) due to the risk of severe hepatotoxicity. Concomitant use with strong CYP3A inhibitors or fluconazole may increase lorlatinib plasma concentrations; dose adjustments may be necessary.
- Pregnancy and Lactation: Lornatib can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for 6 months after the final dose. Men with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the final dose. Breastfeeding is not recommended during treatment and for 7 days after the final dose.
- Hepatic and Renal Impairment: Dose adjustments may be required for patients with severe renal impairment. The recommended dose has not been established for patients with moderate to severe hepatic impairment.
- Monitoring: Regular monitoring of liver function tests, blood pressure, serum cholesterol, and triglycerides is recommended during treatment.
- Consult your healthcare provider for personalized medical advice before starting Lornatib 100mg.
More like this
Find related medicines from trusted suppliers. Explore similar products to ensure you get the right medication for your needs.